Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma (ASND)
NASDAQ:ASND
Ascendis Pharma (ASND) Stock Price & Analysis
398 Followers
ASND Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$85.08 - $161.00
Previous Close$135.1
Volume587.04K
Average Volume (3M)371.67K
Market Cap
$7.65B
Enterprise Value$7.91B
Total Cash (Recent Filing)€399.44M
Total Debt (Recent Filing)€644.26M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Aug 29, 2024EPS Estimate
-$1.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.64
Shares Outstanding56,614,385
10 Day Avg. Volume561,308
30 Day Avg. Volume371,670
Standard Deviation0.12
R-Squared0.06
Alpha0.00501
Financial Highlights & Ratios
Price to Book (P/B)-51.84
Price to Sales (P/S)29.23
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$182.11Price Target Upside34.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Ascendis Pharma News
PremiumCompany Announcements
Ascendis Pharma Details Share Capital Strategy
PremiumCompany Announcements
Ascendis Pharma Expands Capital with Warrants and Shares
PremiumCompany Announcements
FDA Delays Ascendis Pharma’s Drug ReviewBulls Say, Bears Say
Bulls Say
Drug Approval And Market PotentialTransCon PTH in Hypoparathyroidism has demonstrated clear efficacy, and with high confidence in US approval, it's poised to capture a significant market share.
Pipeline And Growth ProspectsWith multiple pipeline catalysts expected and a strong outlook for product diversification, the company shows robust potential for future growth.
Product DevelopmentAscendis is set to present new data for Skytrofa at ENDO 2024, signaling ongoing progress and potential for label expansion to support growth.
Bears Say
Financial PerformanceFirst quarter sales as a two product commercial company were softer than expected.
Product SalesProduct sales of Skytrofa missed estimates, indicating a potential concern for revenue growth.
Regulatory ApprovalThe announcement of a three month PDUFA extension for TransCon PTH (Yorvipath) was unexpected and delays the potential US launch.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ASND FAQ
What was Ascendis Pharma’s price range in the past 12 months?
Ascendis Pharma lowest stock price was $85.08 and its highest was $161.00 in the past 12 months.
What is Ascendis Pharma’s market cap?
Currently, no data Available
When is Ascendis Pharma’s upcoming earnings report date?
Ascendis Pharma’s upcoming earnings report date is Aug 29, 2024 which is in 88 days.
How were Ascendis Pharma’s earnings last quarter?
Ascendis Pharma released its earnings results on May 02, 2024. The company reported -$2.497 earnings per share for the quarter, missing the consensus estimate of -$1.604 by -$0.893.
Is Ascendis Pharma overvalued?
According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued.
Does Ascendis Pharma pay dividends?
Ascendis Pharma does not currently pay dividends.
What is Ascendis Pharma’s EPS estimate?
Ascendis Pharma’s EPS estimate is -$1.48.
How many shares outstanding does Ascendis Pharma have?
Ascendis Pharma has 57,707,440 shares outstanding.
What happened to Ascendis Pharma’s price movement after its last earnings report?
Ascendis Pharma reported an EPS of -$2.497 in its last earnings report, missing expectations of -$1.604. Following the earnings report the stock price went down -2.764%.
Which hedge fund is a major shareholder of Ascendis Pharma?
Among the largest hedge funds holding Ascendis Pharma’s share is RA Capital Management. It holds Ascendis Pharma’s shares valued at 2B.
---
Ascendis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$182.11 (34.80% Upside)
$182.11 (34.80% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 263.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.44%
Trailing 12-Months
Company Description
Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
---
ASND Earnings Call
Q1 2024
0:00 / 0:00
---
ASND Stock 12 Month Forecast
Average Price Target
$182.11
▲(34.80% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Neurocrine
―
Sarepta Therapeutics
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering ASND
1 Year
1 Year Success Rate
17/21 ratings generated profit
1 Year Average Return
+31.41%
reiterated a buy rating 12 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 80.95% of your transactions generating a profit, with an average return of +31.41% per trade.
---